268:HKEXKingdee International Software Group Co., Ltd. Analysis

OLBA Healthcare is trading just above its identified support of 1,995 JPY, with the price sitting below the 20‑day, 50‑day and 200‑day moving averages, indicating a short‑term downside bias. The RSI of ~30 suggests the stock is oversold, while a bearish MACD histogram reinforces recent momentum weakness, though volume is on the rise, hinting at potential buying interest. Fundamentally, the company appears attractively priced – a trailing PE of roughly 9.6 versus an industry average of 24.3 and a price‑to‑book below 1.0 point to a clear valuation discount. Dividend yield sits at 4% with a payout ratio under 40%, supporting the case for income‑focused investors, and a modest debt‑to‑equity of 27% combined with ample cash reserves mitigates balance‑sheet concerns. Revenue growth is modest at around 4‑5% and profit margins are thin, which tempers enthusiasm but does not outweigh the valuation and income advantages. Overall, the stock presents a blend of value and modest growth attributes, with upside potential if technical pressure eases and the dividend remains sustainable.